Skip to main content
. 2023 Sep 4;9:331. doi: 10.1038/s41420-023-01630-8

Fig. 5. In vitro and in vivo experiments confirmed that CRTC3 knockout sensitizes HCC cells to sorafenib treatment by inducing ferroptosis.

Fig. 5

a CRTC3-KO, CRTC3-WT Hep3B, and HepG2 cells were treated with various doses of sorafenib, after which CCK-8 assays were used to assess short-term cell viability (n = 6). b Colony formation assays were performed to assess long-term cell viability after treatment with sorafenib (2.5 μM) (n = 3). c CCK-8 assays showed that inhibition of cell growths after sorafenib treatment (5 μM) were rescued by Ferrostatin-1 (10 μM) and PRGL493 (5 μM) treatment of CRTC3-KO Hep3B cells (n = 6). d Changes in tumor volumes over time of mice implanted with CRTC3-KO or CRTC3-WT Hep3B cells and treated with or without sorafenib (n = 6). e, f Measures of tumor weights and tumor volumes at the endpoint of the study (n = 6). g Representative images (six random visual fields) of HE, Ki-67, CRTC3, and GPx4 staining of tumor samples from CRTC3-KO and CRTC3-WT groups (without treatment). Immunohistochemical scores (n = 3) showed that GPx4 expressions were significantly elevated after CRTC3 knockout. Scale bar: 100 μm. *P < 0.05; **P < 0.01; ***P < 0.001; Student’s t test.